• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bristol-Myers Squibb Co.

Bristol-Myers Squibb taps Taris’ drug-release tech for bladder cancer trial

December 20, 2017 By Sarah Faulkner

Taris Biomedical

Bristol-Myers Squibb (NYSE:BMY) and Taris Biomedical have inked a deal to combine Taris’ investigational GemRIS drug-releasing tech with the pharma company’s PD-1 immune checkpoint inhibitor, Opdivo, in a Phase Ib muscle invasive bladder cancer trial. As part of the collaboration, Bristol-Myers has also made an equity investment in Lexington, Mass.-based Taris. Taris’ GemRIS system is designed […]

Filed Under: Clinical Trials, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Taris Biomedical

Lung cancer expert: Smoking stigma still hurting patients, families and research

November 30, 2017 By Sarah Faulkner

Lungs

A number of therapies designed to treat patients with lung cancer have been approved this year, including products from Novartis (NYSE:NVS), Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY).  That progress is exciting for Dr. Fred Hirsch, the head of the International Association for the Study of Lung Cancer. “We do have a lot of good things to tell the […]

Filed Under: Clinical Trials, Featured, Immunotherapy, Oncology, Pharmaceuticals, Research & Development, Respiratory Tagged With: Bristol-Myers Squibb Co., Merck, Novartis

Awaiting tax reform clarity, Pfizer delays potential M&A

August 1, 2017 By Sarah Faulkner

Pfizer

(Reuters) – Pfizer‘s (NYSE:PFE) chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target’s value. The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull […]

Filed Under: Featured, MassDevice Earnings Roundup, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Pfizer Inc.

Ocular Therapeutix founder & CEO Sawhney to step down | Personnel Moves – June 23, 2017

June 23, 2017 By Sarah Faulkner

Ocular Therapeutix

The president & CEO of Ocular Therapeutix (NSDQ:OCUL), Amarpreet Sawhney, is slated to step down from the company that he helped start in 2006. He will serve as the board’s executive chairman for 1 year, unless he decides to leave earlier. The company wrote in a regulatory filing that “his service will be automatically renewed for […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Biogen Idec, Bristol-Myers Squibb Co., etonpharmaceuticals, nanotherapeutics, Novartis, Ocular Therapeutix, Pulmatrix Inc., Valeant Pharmaceuticals

Bristol-Myers Squibb launches prefilled syringe option for arthritis drug

June 8, 2017 By Sarah Faulkner

Bristol-Myers Squibb

Bristol-Myers Squibb (NYSE:BMY) launched a subcutaneous administration option for Orencia, a biologic indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients who are at least 2 years old. The prefilled syringe enables physicians, caregivers and patients to administer Orencia at home. Orencia is traditionally administered via IV infusion. “The data supporting this […]

Filed Under: Drug-Device Combinations, Featured, Pediatrics Tagged With: Bristol-Myers Squibb Co.

Sanofi promotes Sibold to exec VP of Sanofi Genzyme | Personnel Moves – April 13, 2017

April 17, 2017 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) said at the start of April that it promoted Bill Sibold to exec VP of Sanofi Genzyme, effective July 1, 2017. Sibold succeeds Dr. David Meeker, who is slated to leave the company at the end of June. Sibold is the head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization. He […]

Pages: Page 1 Page 2

Filed Under: Drug-Device Combinations, Featured, Personnel, Wall Street Beat Tagged With: Abbott Laboratories, bausch&lomb, Biogen Idec, Bristol-Myers Squibb Co., Gerresheimer AG, GlucoMe, Mylan, Ocular Therapeutix, Pulmatrix Inc., Sanofi-Aventis

Trump FDA pick to recuse himself from agency decisions involving 20 companies

March 29, 2017 By Sarah Faulkner

FDA

Donald Trump’s nominee to head the FDA, Dr. Scott Gottlieb, reportedly told ethics officials at the Office of Government Ethics he plans to recuse himself for 1 year from agency decisions on more than 20 companies, including GlaxoSmithKline (NYSE:GSK) and Bristol-Myers Squibb (NYSE:BMY). Gottlieb has received millions of dollars for his roles as advisor, paid speaker […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Regulatory/Compliance, Wall Street Beat Tagged With: Biogen Idec, Bristol-Myers Squibb Co., GlaxoSmithKline plc, Merck

Sanofi gains on Q4 results; a look at some of the top drug-delivery earners in 2016

March 22, 2017 By Sarah Faulkner

Prescription drugs

Shares in Sanofi (NYSE:SNY) have gained 11% to $44.58 apiece since the company released its 4th-quarter and full year 2016 financial results in February. The French company posted profits of $731.5 million on sales of $8.21 billion for the 3 months ended Dec. 31, for bottom-line growth of 136.5% on sales growth of 3.3% compared with […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb Co., C.R. Bard, Catalent, Eli Lilly & Co., GlaxoSmithKline plc, Medtronic, Merck, Mylan, Novartis, Roche, Sanofi-Aventis, Teva Pharmaceuticals

Bristol-Myers prices $1.5B senior notes offering

February 23, 2017 By Sarah Faulkner

Bristol-Myers Squibb

Bristol-Myers Squibb (NYSE:BMY) said today that it has agreed to sell $1.5 billion of senior unsecured notes in an underwritten public offering. The offering includes $750 million in  1.6% senior notes due in 2019 and $750 million in 3.3% senior notes due in 2027, according to the New York-based company. Bristol-Myers said it plans to […]

Filed Under: Featured, Funding Roundup Tagged With: Bristol-Myers Squibb Co.

Bristol-Myers, PsiOxus land licensing agreement

December 20, 2016 By Sarah Faulkner

Bristol-Myers, PsiOxus land licensing agreement

Bristol-Myers Squibb (NYSE:BMY) said today that it landed an exclusive licensing agreement for PsiOxus Therapeutics‘ ‘armed’ oncolytic virus, NG-348, for the treatment of solid tumors. According to the agreement, Bristol-Myers will pay PsiOxus $50 million upfront and will assume responsibility for global clinical development and commercialization. PsiOxus will be eligible for $886 million in development, regulatory and […]

Filed Under: Clinical Trials, Featured, Immunotherapy, Oncology, Preclinical Trials, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., PsiOxus Therapeutics

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS